帕金森病中的胆碱能系统改变:新兴治疗方法
帕金森病患者不同脑区可出现异质性胆碱能系统改变,这些改变与多巴胺能治疗难治的运动和非运动临床特征相关,并可在系统层面框架内概念化。胆碱能改变的地形与睡眠、认知、运动、视听觉感知和自主神经功能相关的神经环路重叠。新的药物和神经刺激方法可靶向胆碱能系统以治疗帕金森病的运动和非运动特征。
要点
- 帕金森病胆碱能系统改变呈异质性,与多巴胺能治疗难治的运动和非运动特征相关。
- 认知网络枢纽的胆碱能缺陷比全脑胆碱能改变更能预测认知缺陷。
- 孤立性快速眼动睡眠行为障碍者和认知正常帕金森病患者海马胆碱能活动增高,提示早期代偿。
核心结论
- 帕金森病患者不同脑区可出现异质性胆碱能系统改变,这些改变与多巴胺能治疗难治的运动和非运动临床特征相关。
- 新的药物和神经刺激方法可靶向胆碱能系统以治疗帕金森病的运动和非运动特征。
研究设计与样本
- 原文未报告研究设计。
主要发现
- 认知网络枢纽内的胆碱能缺陷比全脑胆碱能改变更能预测认知缺陷。
- 姿势不稳和步态困难与丘脑、尾状核、边缘系统、新皮质和小脑节点的胆碱能系统改变相关。
- 胆碱能系统缺陷也可涉及外周器官。
- 孤立性快速眼动睡眠行为障碍者中脑桥被盖胆碱能神经元活动增高,认知正常帕金森病患者海马胆碱能活动增高,提示帕金森病前驱期和早期存在代偿。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In patients with Parkinson's disease, heterogeneous cholinergic system changes can occur in different brain regions. These changes correlate with a range of clinical features, both motor and non-motor, that are refractory to dopaminergic therapy, and can be conceptualised within a systems-level framework in which nodal deficits can produce circuit dysfunctions. The topographies of cholinergic changes overlap with neural circuitries involved in sleep and cognitive, motor, visuo-auditory perceptual, and autonomic functions. Cholinergic deficits within cognition network hubs predict cognitive deficits better than do total brain cholinergic changes. Postural instability and gait difficulties are associated with cholinergic system changes in thalamic, caudate, limbic, neocortical, and cerebellar nodes. Cholinergic system deficits can involve also peripheral organs. Hypercholinergic activity of mesopontine cholinergic neurons in people with isolated rapid eye movement (REM) sleep behaviour disorder, as well as in the hippocampi of cognitively normal patients with Parkinson's disease, suggests early compensation during the prodromal and early stages of Parkinson's disease. Novel pharmacological and neurostimulation approaches could target the cholinergic system to treat motor and non-motor features of Parkinson's disease.
引用
- Bohnen NI, Yarnall AJ, Weil RS, et al. Cholinergic system changes in Parkinson's disease: emerging therapeutic approaches. Lancet Neurol. 2022. PMID: 35131038. doi:10.1016/S1474-4422(21)00377-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。